April 6, 2023
06 April 2023 LungLife AI, Inc. (the “Company” or “LungLife”) Publication of Annual Report and Accounts & Notice of AGM LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that the Annual Report and Accounts, Notice of Annual General Meeting ("AGM"), Form of Direction and associated Form of Proxy are now […]
• Read MoreMarch 14, 2023
14 March 2023 LungLife AI, Inc. (the “Company” or “LungLife”) Appointment of Joint Broker LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces the appointment of Goodbody as the Company's Joint Broker with immediate effect. Investec Bank plc remains Nominated Adviser and Joint Broker to the Company. Click HERE for […]
• Read MoreMarch 13, 2023
13 March 2023 LungLife AI, Inc. (the “Company” or “LungLife”) Statement re. Silicon Valley Bank LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, is aware of media reports indicating the closure of Silicon Valley Bank (“SVB”). The Company does not hold any cash at SVB, nor does it have a […]
• Read MoreMarch 7, 2023
7 March 2023 LungLife AI, Inc. (the “Company” or “LungLife”) Nodule evaluation using LungLB® projected to be cost-effective in US healthcare system Data strongly support payor coverage of indeterminate lung nodule evaluation using LungLB® in peer-reviewed publication in the Journal of Medical Economics. LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung […]
• Read MoreFebruary 27, 2023
27 February 2023 LungLife AI, Inc. (the “Company” or “LungLife”) Nodule evaluation using LungLB® projected to be cost-effective in US healthcare system Data strongly support payor coverage of indeterminate lung nodule evaluation using LungLB® in peer-reviewed publication in the Journal of Medical Economics LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung […]
• Read MoreFebruary 20, 2023
20 February 2023 LungLife AI, Inc. (the “Company” or “LungLife”) Preliminary audited results for year ended 31 December 2022 LungLife to report financial results for full-year 2022 LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces its audited preliminary results for the year ended 31 December 2022. Summary and Highlights […]
• Read MoreFebruary 8, 2023
LungLife AI, Inc. (the “Company” or “LungLife”) Notice of Results Investor Presentation LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, will announce its full year results for the year ended 31 December 2022 on Monday 20 February 2023. Investor presentation Paul Pagano, Chief Executive Officer, and David Anderson, Chief Financial […]
• Read MoreNovember 30, 2022
LungLife AI, Inc. (the “Company” or “LungLife”) Final Pricing Determination Medicare Grants Pricing for LungLife’s LungLB® Early Lung Cancer Diagnostic LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that the Centers for Medicare & Medicaid Services (“CMS”) has granted a price at $2,030 per test for the LungLB® early […]
• Read MoreNovember 30, 2022
LungLife AI, Inc. (the “Company” or “LungLife”) Total Voting Rights The Company’s total issued share capital consists of 25,485,982 Ordinary Shares of US $0.0001 each ("Ordinary Shares") with one voting right per Ordinary Share. There are no Ordinary Shares held in treasury. The total number of voting rights in the Company is therefore 25,485,982. This […]
• Read More
LungLife AI licensure/accreditation information posted here.